5 Citations (Scopus)

Abstract

Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.

Original languageEnglish
Pages (from-to)85-106
Number of pages22
JournalJournal of Ocular Pharmacology and Therapeutics
Volume34
Issue number1-2
DOIs
StatePublished - 1 Jan 2018

Fingerprint

Glaucoma
Retinal Diseases
Western World
Retinal Ganglion Cells
Aqueous Humor
Blindness
Optic Nerve
Intraocular Pressure
Neurodegenerative Diseases
Pharmacology
Mutation
Primary Open Angle Glaucoma
Neuroprotection
Therapeutics

Keywords

  • drug targets
  • glaucoma
  • neuroprotection

Cite this

@article{68dd154c8052410e970cdfed62cc0555,
title = "Targets of neuroprotection in glaucoma",
abstract = "Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.",
keywords = "drug targets, glaucoma, neuroprotection",
author = "Shaoqing He and Stankowska, {Dorota Luiza} and Ellis, {Dorette Zoe} and Raghu Krishnamoorthy and Thomas Yorio",
year = "2018",
month = "1",
day = "1",
doi = "10.1089/jop.2017.0041",
language = "English",
volume = "34",
pages = "85--106",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "1-2",

}

TY - JOUR

T1 - Targets of neuroprotection in glaucoma

AU - He, Shaoqing

AU - Stankowska, Dorota Luiza

AU - Ellis, Dorette Zoe

AU - Krishnamoorthy, Raghu

AU - Yorio, Thomas

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.

AB - Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.

KW - drug targets

KW - glaucoma

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=85041904060&partnerID=8YFLogxK

U2 - 10.1089/jop.2017.0041

DO - 10.1089/jop.2017.0041

M3 - Article

C2 - 28820649

AN - SCOPUS:85041904060

VL - 34

SP - 85

EP - 106

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 1-2

ER -